Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.1%

7 terminated/withdrawn out of 339 trials

Success Rate

92.0%

+5.5% vs industry average

Late-Stage Pipeline

19%

65 trials in Phase 3/4

Results Transparency

6%

5 of 81 completed trials have results

Key Signals

21 recruiting5 with results

Enrollment Performance

Analytics

Phase 2
126(44.7%)
Phase 3
48(17.0%)
N/A
45(16.0%)
Phase 1
40(14.2%)
Phase 4
17(6.0%)
Early Phase 1
6(2.1%)
282Total
Phase 2(126)
Phase 3(48)
N/A(45)
Phase 1(40)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (339)

Showing 20 of 339 trials
NCT07013461Recruiting

International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer

Role: collaborator

NCT07500428Recruiting

Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models

Role: collaborator

NCT07411768Not ApplicableNot Yet Recruiting

Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement

Role: collaborator

NCT07457944Completed

Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients

Role: collaborator

NCT06668025Not ApplicableCompleted

MxA-Guided Antiviral Treatment in Respiratory Viral Infections

Role: collaborator

NCT06061536Phase 2Completed

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

Role: collaborator

NCT06560489Phase 1Completed

Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients

Role: collaborator

NCT05577312Phase 1Enrolling By Invitation

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Role: collaborator

NCT07275853Phase 1Not Yet Recruiting

Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

Role: collaborator

NCT06736275Early Phase 1Active Not Recruiting

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

Role: collaborator

NCT07259278Not ApplicableRecruiting

Intelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients

Role: collaborator

NCT05741359Phase 1Recruiting

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Role: collaborator

NCT06085690Not ApplicableRecruiting

Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science

Role: collaborator

NCT06917664Phase 4Recruiting

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Role: collaborator

NCT06685601Not ApplicableRecruiting

An Intervention Study on Transcranial Photobiomodulation in Children With Attention Deficit Hyperactivity Disorder

Role: collaborator

NCT07002346Phase 3Not Yet Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: collaborator

NCT07000617Phase 2Recruiting

A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

Role: collaborator

NCT06998108Phase 3Recruiting

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

Role: collaborator

NCT06876610Recruiting

Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer

Role: collaborator

NCT06453902Phase 2Recruiting

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Role: collaborator